Lanifibranor—a pan-agonist affecting PPARα, PPARγ and PPARβ/δ—is currently showing promising results, achieving NASH resolution and fibrosis regression in a phase IIb clinical trial (NCT03008070) [154]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.